Latest Conference Articles

While the current ADA guidelines recommend targeting HbA1c levels to below 8% for high-risk patients with diabetes, reducing the level to 5.7% dose not raise CVD or overall mortality risk, according to a recent study.

A novel algorithm for patient self-adjustment of prandial insulin dose could make it easier for patients who are poorly-controlled on basal insulin to add meal-time insulin.

In patients with type 2 diabetes currently taking metformin, treatment with combination exenatide plus insulin glargine decreased fasting glucose and resulted in greater weight loss compared to treatment with insulin lispro plus insulin glargine.

Study shows dulaglutide improved glycemic control in patients at 52 weeks compared to sitagliptin, but with a higher rate of adverse events.

Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.

Hypertriglyceridemia combined with insulin resistance may lead to increased platelet activation in women with polycystic ovary syndrome (PCOS).

Insulin sensitivity improved after three nights of adequate sleep in nondiabetic men after days of inadequate sleep.

Study results suggest that tight glycemic control is associated with decreased length of stay and improved mortality.

Results of a recent meta-analysis suggest lower rates of hypoglycemia with insulin degludec in obese patients when compared with insulin glargine.

Study shows that 12 weeks of vitamin D supplementation in obese adolescents does not affect cardiometabolic risk factors.

At ENDO 2013, an expert panel discussed the consensus statement on the evaluation and treatment of hypertriglyceridemia and the evidence supporting the recommendations.

Study results show improvements in body composition, intrahepatic lipids, and cardiovascular risk markers in obese men treated with growth hormone for six months compared with placebo.

In cell culture and mice studies, bazedoxifene inhibited estrogen-induced gene expression and cell proliferation in cancer cells, including those that were tamoxifen-resistant.

Initial data show similar efficacy but different costs among injectable insulin treatments for patients who fail oral antidiabetic drugs.

News and updates about the American Diabetes Association 73rd Scientific Sessions.

A recent study suggests that skipping breakfast in overweight women may lead to insulin resistance.

According to a recent retrospective study, orlistat is not associated with hepatotoxic effects after one year of use and it contributes to weight loss in obese patients.

In patients previously treated with bisphosponate, denosumab was associated with greater improvements in bone mineral density than ibandronate and risedronate.

Phase III studies show LDMP to be safe and effective for treatment of vasomotor symptoms in menopausal women.

News and updates about the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013).

To prepare for coming changes at the CMS driven by the Affordable care Act, multiple sclerosis care centers should begin to develop MS-specific electronic health record templates that record clinical outcome measures.

With so many different interdependent symptoms affecting MS pathogenesis, effective treatment requires intervention by a multidisciplinary team, with progress assessed by validated instruments that measure variables such as physical health, psychological health, and social relationships.

Experimental data suggest that memory-retraining exercises and other cognitive rehabilitation techniques may improve memory acquisition and retention in patients with multiple sclerosis.

Pain is a common symptom in patients with multiple sclerosis (MS), with some studies showing that clinically significant pain associated with their disease is experienced by more than half of patients with MS.

Comprehensive care for patients with MS starts with medical treatment of the symptoms of their disease, but must also include intervention by clinicians who can address the mental, physical, and social challenges experienced by many patients.

Early diagnosis is one of the most important characteristics of effective MS treatment, since the greatest irreversible disabilities tend to occur early in the course of MS disease progression.

Physicians must consider a range of factors when initiating treatment with disease-modifying drug therapy and be prepared to switch to another first- or second-line option if the patient fails to respond.

Monoclonal antibodies, chimeric molecules, and other immunomodulating drugs and novel approaches hold real promise for effectively treating multiple sclerosis.

Treating patients with multiple sclerosis who opt to use only supplements and other complementary and alternative approaches requires a great deal of tact and education, and input and support from all members of the multidisciplinary treatment team.

News and updates about ENDO 2013: The Endocrine Society 95th Annual Meeting & Scientific Expo.